AAAAAA

   
Results: 1-9 |
Results: 9
PRETARGETED RADIOIMMUNOTHERAPY(TM) WITH ANTIBODY-STREPTAVIDIN AND Y-90 DOTA-BIOTIN (AVICIDIN(R)) - RESULT OF A DOSE-ESCALATION STUDY
Authors: BREITZ H KNOX S WEIDEN P GORIS M MURTHA A BRYAN J AXWORTHY D SEILER C SU FM BEAUMIER P RENO J
Citation: H. Breitz et al., PRETARGETED RADIOIMMUNOTHERAPY(TM) WITH ANTIBODY-STREPTAVIDIN AND Y-90 DOTA-BIOTIN (AVICIDIN(R)) - RESULT OF A DOSE-ESCALATION STUDY, The Journal of nuclear medicine, 39(5), 1998, pp. 272-272
PRETARGETED RADIOIMMUNOTHERAPY IN TUMORED MICE USING AN IN-VIVO PB-212 BI-212 GENERATOR/
Authors: SU FM BEAUMIER P AXWORTHY D RENO J FISHER D FRITZBERG A
Citation: Fm. Su et al., PRETARGETED RADIOIMMUNOTHERAPY IN TUMORED MICE USING AN IN-VIVO PB-212 BI-212 GENERATOR/, The Journal of nuclear medicine, 39(5), 1998, pp. 354-354
EXPERIENCE WITH ALUMINUM PERRHENATE TARGETS FOR REACTOR PRODUCTION OFHIGH SPECIFIC ACTIVITY RE-186
Authors: EHRHARDT GJ BLUMER ME SU FM VANDERHEYDEN JL FRITZBERG AR
Citation: Gj. Ehrhardt et al., EXPERIENCE WITH ALUMINUM PERRHENATE TARGETS FOR REACTOR PRODUCTION OFHIGH SPECIFIC ACTIVITY RE-186, Applied radiation and isotopes, 48(1), 1997, pp. 1-4
(186)RE-LABELED ANTIBODIES TO P185(HER2) AS HER2-TARGETED RADIOIMMUNOPHARMACEUTICAL AGENTS - COMPARISON OF PHYSICAL AND BIOLOGICAL CHARACTERISTICS WITH I-125 AND I-131-LABELED COUNTERPARTS
Authors: KOTTS CE SU FM LEDDY C DODD T SCATES S SHALABY MR WIRTH CM GILTINAN D SCHROFF RW FRITZBERG AR SHEPARD HM SLAMON DJ HUTCHINS BM
Citation: Ce. Kotts et al., (186)RE-LABELED ANTIBODIES TO P185(HER2) AS HER2-TARGETED RADIOIMMUNOPHARMACEUTICAL AGENTS - COMPARISON OF PHYSICAL AND BIOLOGICAL CHARACTERISTICS WITH I-125 AND I-131-LABELED COUNTERPARTS, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(2), 1996, pp. 133-144
IN-111 Y-90 DUAL-ISOTOPE SCINTILLATION-COUNTING METHOD FOR PATIENT SAMPLES FROM PRETARGETED CANCER-THERAPY PHASE-I TRIAL/
Authors: SU FM HICKEY JJ TAYLOR C BEAUMIER P
Citation: Fm. Su et al., IN-111 Y-90 DUAL-ISOTOPE SCINTILLATION-COUNTING METHOD FOR PATIENT SAMPLES FROM PRETARGETED CANCER-THERAPY PHASE-I TRIAL/, The Journal of nuclear medicine, 37(5), 1996, pp. 636-636
CHARACTERIZATION AND PREVENTION OF RADIOLYTIC DECOMPOSITION OF HIGH SPECIFIC ACTIVITY Y-90 DOTA-BIOTIN IN ANTIBODY PRETARGETING
Authors: SU FM HICKEY JJ HOBSON LJ FRITZBERG AR RENO JM
Citation: Fm. Su et al., CHARACTERIZATION AND PREVENTION OF RADIOLYTIC DECOMPOSITION OF HIGH SPECIFIC ACTIVITY Y-90 DOTA-BIOTIN IN ANTIBODY PRETARGETING, The Journal of nuclear medicine, 37(5), 1996, pp. 726-726
EXPERIENCE WITH ALUMINUM PERRHENATE TARGETS FOR PRODUCTION OF RE-186 AND RE-188
Authors: BLUMER ME EHRHARDT GJ SU FM
Citation: Me. Blumer et al., EXPERIENCE WITH ALUMINUM PERRHENATE TARGETS FOR PRODUCTION OF RE-186 AND RE-188, The Journal of nuclear medicine, 35(5), 1994, pp. 160000242-160000242
HUMAN ANTI-MOUSE ANTIBODY SUPPRESSION WITH CYCLOSPORINE-A
Authors: WEIDEN PL WOLF SB BREITZ HB APPELBAUM JW SEILER CA MALLETT R BJORN MJ SU FM FER NF SALK D
Citation: Pl. Weiden et al., HUMAN ANTI-MOUSE ANTIBODY SUPPRESSION WITH CYCLOSPORINE-A, Cancer, 73(3), 1994, pp. 1093-1097
A PHASE-I TRIAL OF A RHENIUM 186-LABELED MONOCLONAL-ANTIBODY ADMINISTERED INTRAPERITONEALLY IN OVARIAN-CARCINOMA - TOXICITY AND CLINICAL-RESPONSE
Authors: JACOBS AJ FER M SU FM BREITZ H THOMPSON J GOODGOLD H CAIN J HEAPS J WEIDEN P
Citation: Aj. Jacobs et al., A PHASE-I TRIAL OF A RHENIUM 186-LABELED MONOCLONAL-ANTIBODY ADMINISTERED INTRAPERITONEALLY IN OVARIAN-CARCINOMA - TOXICITY AND CLINICAL-RESPONSE, Obstetrics and gynecology, 82(4), 1993, pp. 586-593
Risultati: 1-9 |